Gut-microbiota-on-a-chip: an enabling field for physiological research.
Gut-microbiota-on-a-chip: an enabling field for physiological research.
复制标题
DOI：
10.21037/mps.2018.09.01
复制
发表时间：
2018-10
期刊：
影响因子：
--
通讯作者：
G. Trujillo‐de Santiago;Matías José Lobo-Zegers;S. L. Montes-Fonseca;Y. S. Zhang;M. M. Álvarez-M.
中科院分区：
文献类型：
--
作者：
G. Trujillo‐de Santiago;Matías José Lobo-Zegers;S. L. Montes-Fonseca;Y. S. Zhang;M. M. Álvarez-M.
今天，压倒性的科学证据证实，肠道微生物群在人类健康中发挥着核心作用。在过去十年中，基于对人类粪便样本或动物模型（主要是啮齿动物）进行分析的实验工作，关于人类肠道微生物群与人类健康之间相互作用的知识发展迅速。现在，通过使用体外系统（即肠道微生物群芯片系统），可以对这种相互作用进行更详细和更具成本效益的描述，该系统概括了微生物群与人类细胞之间相互作用的关键方面。在这里，我们回顾了最近设计和使用开创性芯片平台的例子，用于研究人类微生物群和人体微组织的代表性成员之间的串扰。在这些系统中，结合使用最先进的微流体、生物材料、细胞培养技术、经典微生物学和遗传表达谱的结合，已经融合在芯片肠道平台的开发上，能够重现人类微生物群和宿主人体组织之间相互作用的关键特征。我们预见，新型微加工技术和干细胞技术的整合将进一步加速更复杂和生理相关的芯片上微生物群平台的发展。反过来，这将促进更快地获取有关人类微生物群的知识，并将使对如何控制或预防疾病的理解取得重要进展。
Overwhelming scientific evidence today confirms that the gut microbiota is a central player in human health. Knowledge about interactions between human gut microbiota and human health has evolved rapidly in the last decade, based on experimental work involving analysis of human fecal samples or animal models (mainly rodents). A more detailed and cost-effective description of this interplay is now being enabled by the use of in vitro systems (i.e., gut-microbiota-on-chip systems) that recapitulate key aspects of the interaction between microbiota and human cells. Here, we review recent examples of the design and use of pioneering on-chip platforms for the study of the cross-talk between representative members of human microbiota and human microtissues. In these systems, the combined use of state-of-the-art microfluidics, biomaterials, cell culture techniques, classical microbiology, and a touch of genetic expression profiling have converged for the development of gut-on-chip platforms capable of recreating key features of the interplay between human microbiota and host human tissues. We foresee that the integration of novel microfabrication techniques and stem cell technologies will further accelerate the development of more complex and physiologically relevant microbiota-on-chip platforms. In turn, this will foster the faster acquisition of knowledge regarding human microbiota and will enable important advances in the understanding of how to control or prevent disease.